Peregrine Pharmaceuticals (NASDAQ: CDMO) and Synlogic (NASDAQ:SYBX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, dividends, profitability, risk and institutional ownership.
Volatility and Risk
Peregrine Pharmaceuticals has a beta of 2.73, indicating that its share price is 173% more volatile than the S&P 500. Comparatively, Synlogic has a beta of 3.17, indicating that its share price is 217% more volatile than the S&P 500.
This table compares Peregrine Pharmaceuticals and Synlogic’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings and recommmendations for Peregrine Pharmaceuticals and Synlogic, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Peregrine Pharmaceuticals presently has a consensus target price of $10.00, suggesting a potential upside of 175.48%. Synlogic has a consensus target price of $19.67, suggesting a potential upside of 103.80%. Given Peregrine Pharmaceuticals’ stronger consensus rating and higher possible upside, research analysts clearly believe Peregrine Pharmaceuticals is more favorable than Synlogic.
Valuation & Earnings
This table compares Peregrine Pharmaceuticals and Synlogic’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Peregrine Pharmaceuticals||$57.63 million||2.85||-$28.15 million||($0.70)||-5.19|
Synlogic has lower revenue, but higher earnings than Peregrine Pharmaceuticals. Peregrine Pharmaceuticals is trading at a lower price-to-earnings ratio than Synlogic, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
18.7% of Peregrine Pharmaceuticals shares are owned by institutional investors. Comparatively, 64.2% of Synlogic shares are owned by institutional investors. 2.5% of Peregrine Pharmaceuticals shares are owned by insiders. Comparatively, 18.6% of Synlogic shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Synlogic beats Peregrine Pharmaceuticals on 8 of the 13 factors compared between the two stocks.
Peregrine Pharmaceuticals Company Profile
Avid Bioservices, Inc., formerly Peregrine Pharmaceuticals, Inc., incorporated on September 25, 1996, is a biopharmaceutical company. The Company is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts. The Company delivers pharmaceutical products through its contract manufacturing business and through licensing its development-stage immunotherapy products. The company provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. Its services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The Company also provides a variety of process development activities, including cell line development and optimization.
Synlogic Company Profile
Synlogic, Inc., formerly Mirna Therapeutics, Inc., is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). It is also focused on Synthetic Biotic medicines to address other conditions, including inflammatory bowel disease , cancer and metabolic conditions, such as diabetes and obesity. The Company’s synthetic biotic medicines leverages the tools and principles of synthetic biology to genetically reengineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The Company’s pipeline includes synthetic biotic medicines for the treatment of inborn errors of metabolism (IEM). It is developing SYNB1020 for the treatment of UCD and HE. It is developing SYNB1618 for the treatment of PKU.
Receive News & Ratings for Peregrine Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Peregrine Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.